keyword
https://read.qxmd.com/read/38605010/deficiency-of-the-hgf-met-pathway-leads-to-thyroid-dysgenesis-by-impeding-late-thyroid-expansion
#21
JOURNAL ARTICLE
Ya Fang, Jia-Ping Wan, Zheng Wang, Shi-Yang Song, Cao-Xu Zhang, Liu Yang, Qian-Yue Zhang, Chen-Yan Yan, Feng-Yao Wu, Sang-Yu Lu, Feng Sun, Bing Han, Shuang-Xia Zhao, Mei Dong, Huai-Dong Song
The mechanisms of bifurcation, a key step in thyroid development, are largely unknown. Here we find three zebrafish lines from a forward genetic screening with similar thyroid dysgenesis phenotypes and identify a stop-gain mutation in hgfa and two missense mutations in met by positional cloning from these zebrafish lines. The elongation of the thyroid primordium along the pharyngeal midline was dramatically disrupted in these zebrafish lines carrying a mutation in hgfa or met. Further studies show that MAPK inhibitor U0126 could mimic thyroid dysgenesis in zebrafish, and the phenotypes are rescued by overexpression of constitutively active MEK or Snail, downstream molecules of the HGF/Met pathway, in thyrocytes...
April 11, 2024: Nature Communications
https://read.qxmd.com/read/38602773/intracranial-hemorrhage-caused-by-dabrafenib-and-trametinib-therapy-for-metastatic-melanoma
#22
JOURNAL ARTICLE
Aymeric Hennemann, Eve Puzenat, Marion Decreuse, Fabrice Vuillier, Charlée Nardin, François Aubin
Although generally well tolerated compared with chemotherapy, molecular targeted therapy used in metastatic melanoma may be associated with life-threatening toxicity. We report the case of a patient with metastatic melanoma treated by dabrafenib plus trametinib who developed intracranial hemorrhage. Physicians should be aware of this rare but life-threatening adverse event of B-rapidly accelerated fibrosarcoma (BRAF) and mitogen-activated protein kinase kinase (MEK). However, they should be careful about the bleeding origin, which can prove to be a new onset of melanoma metastasis or anticoagulation overdose, or even an uncontrolled arterial hypertension...
April 5, 2024: Melanoma Research
https://read.qxmd.com/read/38601760/outcomes-of-non-small-cell-lung-cancer-patients-with-non-v600e-braf-mutations-a-series-of-case-reports-and-literature-review
#23
Raluca Lazar, Cathie Fischbach, Roland Schott, Laura Somme
Non-small cell lung cancer (NSCLC) is the most prevalent form of lung cancer, accounting for approximately 85% of cases of lung cancer. The standard first-line therapy for patients without oncogenic driver metastatic NSCLC is anti PD-L1 immune checkpoint inhibition (ICI) with platinum-based chemotherapy. Approximately 4% of NSCLC patients harbor BRAF mutations; the V600E mutation is the most common. Non-V600 mutations is an heterogeneous population and account for approximately 50% of BRAF -mutated NSCLC. BRAF mutations are classified into 3 functional classes based on their kinase activity and their signaling mechanism...
2024: Frontiers in Oncology
https://read.qxmd.com/read/38601702/engagement-of-akt-and-erk-signaling-pathways-facilitates-infection-of-human-neuronal-cells-with-west-nile-virus
#24
JOURNAL ARTICLE
Wan-Da Tang, Wei-Yang Zhu, Hai-Lin Tang, Ping Zhao, Lan-Juan Zhao
West Nile virus (WNV) is an important neurotropic virus that accounts for the emergence of human arboviral encephalitis and meningitis. The interaction of WNV with signaling pathways plays a key role in controlling WNV infection. We have investigated the roles of the AKT and ERK pathways in supporting WNV propagation and modulating the inflammatory response following WNV infection. WNV established a productive infection in neuronal cell lines originated from human and mouse. Expression of IL-11 and TNF-α was markedly up-regulated in the infected human neuronal cells, indicating elicitation of inflammation response upon WNV infection...
March 2024: Journal of Virus Eradication
https://read.qxmd.com/read/38601651/diagnostic-and-prognostic-role-of-long-non-coding-rnas-lncrnas-in-metastatic-melanoma-patients-with-braf-gene-mutation-receiving-braf-and-mek-inhibitors
#25
JOURNAL ARTICLE
Łukasz Galus, Tomasz Kolenda, Michał Michalak, Jacek Mackiewicz
Melanoma is a cancer with a high incidence rate that, despite the significant development of therapeutic options, still remains a major problem. The identification of biomarkers to select the right therapy for the right patient is one of the possibilities to improve the prognosis of patients. Potentially, the function of biomarkers could be played long non-coding RNAs (lncRNAs). The expression of selected 90 lncRNAs in serum from 30 metastatic melanoma patients with confirmed mutations in the BRAF V600 E or K gene was studied...
April 15, 2024: Heliyon
https://read.qxmd.com/read/38600093/cdk4-6-inhibition-sensitizes-mek-inhibition-by-inhibiting-cell-cycle-and-proliferation-in-pancreatic-ductal-adenocarcinoma
#26
JOURNAL ARTICLE
Ke Cheng, Zijian Zhou, Qiangxing Chen, Zixin Chen, Yu Cai, He Cai, Shangdi Wu, Pan Gao, Yunqiang Cai, Jin Zhou, Xin Wang, Zhong Wu, Bing Peng
Pancreatic ductal adenocarcinoma (PDAC) is not sensitive to most chemotherapy drugs, leading to poor chemotherapy efficacy. Recently, Trametinib and Palbociclib have promising prospects in the treatment of pancreatic cancer. This article aims to explore the effects of Trametinib on pancreatic cancer and address the underlying mechanism of resistance as well as its reversal strategies. The GDSC (Genomics of Drug Sensitivity in Cancer) and CTD2 (Cancer Target Discovery and Development) were utilized to screen the potential drug candidate in PDAC cell lines...
April 10, 2024: Scientific Reports
https://read.qxmd.com/read/38599894/fosgonimeton-attenuates-amyloid-beta-toxicity-in-preclinical-models-of-alzheimer-s-disease
#27
JOURNAL ARTICLE
Sherif M Reda, Sharay E Setti, Andrée-Anne Berthiaume, Wei Wu, Robert W Taylor, Jewel L Johnston, Liana R Stein, Hans J Moebius, Kevin J Church
Positive modulation of hepatocyte growth factor (HGF) signaling may represent a promising therapeutic strategy for Alzheimer's disease (AD) based on its multimodal neurotrophic, neuroprotective, and anti-inflammatory effects addressing the complex pathophysiology of neurodegeneration. Fosgonimeton is a small-molecule positive modulator of the HGF system that has demonstrated neurotrophic and pro-cognitive effects in preclinical models of dementia. Herein, we evaluate the neuroprotective potential of fosgonimeton, or its active metabolite, fosgo-AM, in amyloid-beta (Aβ)-driven preclinical models of AD, providing mechanistic insight into its mode of action...
April 9, 2024: Neurotherapeutics: the Journal of the American Society for Experimental NeuroTherapeutics
https://read.qxmd.com/read/38594640/assessment-of-the-fret-based-teen-sensor-to-monitor-erk-activation-changes-preceding-morphological-defects-in-a-rasopathy-zebrafish-model-and-phenotypic-rescue-by-mek-inhibitor
#28
JOURNAL ARTICLE
Giulia Fasano, Stefania Petrini, Valeria Bonavolontà, Graziamaria Paradisi, Catia Pedalino, Marco Tartaglia, Antonella Lauri
BACKGROUND: RASopathies are genetic syndromes affecting development and having variable cancer predisposition. These disorders are clinically related and are caused by germline mutations affecting key players and regulators of the RAS-MAPK signaling pathway generally leading to an upregulated ERK activity. Gain-of-function (GOF) mutations in PTPN11, encoding SHP2, a cytosolic protein tyrosine phosphatase positively controlling RAS function, underlie approximately 50% of Noonan syndromes (NS), the most common RASopathy...
April 9, 2024: Molecular Medicine
https://read.qxmd.com/read/38590555/personalized-treatment-concepts-in-extraocular-cancer
#29
REVIEW
Sitong Ju, Alexander C Rokohl, Yongwei Guo, Ke Yao, Wanlin Fan, Ludwig M Heindl
BACKGROUND: The periocular skin is neoplasms-prone to various benign and malignant. Periocular malignancies are more aggressive and challenging to cure and repair than those in other skin areas. In recent decades, immunotherapy has significantly advanced oncology, allowing the autoimmune system to target and destroy malignant cells. Skin malignancies, especially periocular tumors, are particularly sensitive to immunotherapy. This technique has dramatically impacted the successful treatment of challenging tumors...
2024: Adv Ophthalmol Pract Res
https://read.qxmd.com/read/38589300/effect-of-kaempferol-on-modulation-of-vascular-contractility-mainly-through-pkc-and-cpi-17-inactivation
#30
JOURNAL ARTICLE
Hyuk-Jun Yoon, Heui Woong Moon, Young Sil Min, Fanxue Jin, Joon Seok Bang, Uy Dong Sohn, Hyun Dong Je
In this study, we investigated the efficacy of kaempferol (a flavonoid found in plants and plant-derived foods such as kale, beans, tea, spinach and broccoli) on vascular contractibility and aimed to clarify the detailed mechanism underlying the relaxation. Isometric contractions of divested muscles were stored and linked with western blot analysis which was carried out to estimate the phosphorylation of myosin phosphatase targeting subunit 1 (MYPT1) and phosphorylation-dependent inhibitory protein for myosin phosphatase (CPI-17) and to estimate the effect of kaempferol on the RhoA/ROCK/CPI-17 pathway...
April 9, 2024: Biomolecules & Therapeutics
https://read.qxmd.com/read/38588479/treatment-of-cerebral-histiocytosis-with-low-dose-of-cobimetinib-a-report-of-2-cases
#31
JOURNAL ARTICLE
Charlotte Schubert, Insa Schiffmann, Said C Farschtschi, Jean-François Emile, Manuel A Friese
OBJECTIVES: Histiocytic disorders are pathologic expansions of myeloid cells in multiple organs, including the CNS. They share activation of the MAP kinase pathway due to either BRAF V600E variant or other variants in the RAS-RAF-MEK-ERK pathway. The rarity and heterogeneity of the disease only enable therapy through pathophysiologic considerations. METHODS: We present 2 histiocytosis cases without BRAF sequence variants that affect the CNS, one with Erdheim-Chester disease and the other with an unspecified histiocytosis, and their diagnostic and therapeutic challenges...
May 2024: Neurology® Neuroimmunology & Neuroinflammation
https://read.qxmd.com/read/38588399/the-pan-raf-mek-non-degrading-molecular-glue-nst-628-is-a-potent-and-brain-penetrant-inhibitor-of-the-ras-mapk-pathway-with-activity-across-diverse-ras-and-raf-driven-cancers
#32
JOURNAL ARTICLE
Meagan B Ryan, Bradley Quade, Natasha Schenk, Zhong Fang, Marshall Zingg, Steven E Cohen, Brooke M Swalm, Chun Li, Aysegul Ozen, Chaoyang Ye, Maria Stella Ritorto, Xin Huang, Arvin C Dar, Yongxin Han, Klaus P Hoeflich, Michael Hale, Margit Hagel
Alterations in the RAS-MAPK signaling cascade are common across multiple solid tumor types and is a driver for many cancers. NST-628 is a potent pan-RAF-MEK molecular glue that prevents phosphorylation and activation of MEK by RAF, overcoming the limitations of traditional RAS-MAPK inhibitors and leading to deep durable inhibition of the pathway. Cellular, biochemical, and structural analysis of RAF-MEK complexes show that NST-628 engages all isoforms of RAFand prevents the formation of BRAF-CRAF heterodimers, a differentiated mechanism from all current RAF inhibitors...
April 8, 2024: Cancer Discovery
https://read.qxmd.com/read/38585724/pharmacogenomic-synthetic-lethal-screens-reveal-hidden-vulnerabilities-and-new-therapeutic-approaches-for-treatment-of-nf1-associated-tumors
#33
Kyle B Williams, Alex T Larsson, Bryant J Keller, Katherine E Chaney, Rory L Williams, Minu M Bhunia, Garrett M Draper, Tyler A Jubenville, Sue K Rathe, Christopher L Moertel, Nancy Ratner, David A Largaespada
Neurofibromatosis Type 1 (NF1) is a common cancer predisposition syndrome, caused by heterozygous loss of function mutations in the tumor suppressor gene NF1 . Individuals with NF1 develop benign tumors of the peripheral nervous system (neurofibromas), originating from the Schwann cell linage after somatic loss of the wild type NF1 allele, some of which progress further to malignant peripheral nerve sheath tumors (MPNST). There is only one FDA approved targeted therapy for symptomatic plexiform neurofibromas and none approved for MPNST...
March 25, 2024: bioRxiv
https://read.qxmd.com/read/38582811/the-prognostic-value-of-mek-pathway-associated-estrogen-receptor-signaling-activity-for-female-cancers
#34
JOURNAL ARTICLE
Chun Wai Ng, Yvonne T M Tsang, David M Gershenson, Kwong-Kwok Wong
BACKGROUND: Other than for breast cancer, endocrine therapy has not been highly effective for gynecologic cancers. Endocrine therapy resistance in estrogen receptor positive gynecologic cancers is still poorly understood. In this retrospective study, we examined the estrogen receptor (ER) signaling pathway activities of breast, ovarian, endometrial, and cervical cancers to identify those that may predict endocrine therapy responsiveness. METHODS: Clinical and genomic data of women with breast and gynecological cancers were downloaded from cBioPortal for Cancer Genomics...
April 6, 2024: British Journal of Cancer
https://read.qxmd.com/read/38582027/high-throughput-screening-identifies-dasatinib-as-synergistic-with-trametinib-in-low-grade-serous-ovarian-carcinoma
#35
JOURNAL ARTICLE
Robert L Hollis, Richard Elliott, John C Dawson, Narthana Ilenkovan, Rosie M Matthews, Lorna J Stillie, Ailsa J Oswald, Hannah Kim, Marta Llaurado Fernandez, Michael Churchman, Joanna M Porter, Patricia Roxburgh, Asier Unciti-Broceta, David M Gershenson, C Simon Herrington, Mark S Carey, Neil O Carragher, Charlie Gourley
BACKGROUND: Low grade serous ovarian carcinoma (LGSOC) is a distinct histotype of ovarian cancer characterised high levels of intrinsic chemoresistance, highlighting the urgent need for new treatments. High throughput screening in clinically-informative cell-based models represents an attractive strategy for identifying candidate treatment options for prioritisation in clinical studies. METHODS: We performed a high throughput drug screen of 1610 agents across a panel of 6 LGSOC cell lines (3 RAS/RAF-mutant, 3 RAS/RAF-wildtype) to identify novel candidate therapeutic approaches...
April 5, 2024: Gynecologic Oncology
https://read.qxmd.com/read/38580186/a-new-invertebrate-npy-like-polypeptide-zoanpy-from-the-zoanthus-sociatus-as-a-novel-ligand-of-human-npy-y2-receptor-rescues-vascular-insufficiency-via-plc-pkc-and-src-fak-dependent-signaling-pathways
#36
JOURNAL ARTICLE
Qian Chen, Nan Xu, Chen Zhao, Yulin He, Sandy Hio Tong Kam, Xue Wu, Pan Huang, Min Yang, Clarence Tsun Ting Wong, Gandhi Radis-Baptista, Benqin Tang, Guangyi Fan, Guiyi Gong, Simon Ming-Yuen Lee
Our recent multi-omics studies have revealed rich sources of novel bioactive proteins and polypeptides from marine organisms including cnidarians. In the present study, we initially conducted a transcriptomic analysis to review the composition profile of polypeptides from Zoanthus sociatus. Then, a newly discovered NPY-like polypeptide-ZoaNPY was selected for further in silico structural, binding and virtually pharmacological studies. To evaluate the pro-angiogenic effects of ZoaNPY, we employed an in vitro HUVECs model and an in vivo zebrafish model...
April 3, 2024: Pharmacological Research: the Official Journal of the Italian Pharmacological Society
https://read.qxmd.com/read/38577058/safety-and-tolerability-of-topical-trametinib-in-rosacea-results-from-a-phase-i-clinical-trial
#37
JOURNAL ARTICLE
Edward J Wladis, Jacqueline Busingye, Leahruth K Saavedra, Amy Murdico, Alejandro P Adam
PURPOSE: Overactivation of the mitogen activated kinase pathway has been associated with rosacea. We hypothesised that inhibitors of this pathway can be repurposed to alleviate rosacea symptoms. METHODS: In order to test this hypothesis, we designed a double-blind, randomised, placebo-controlled phase I clinical trial to assess the safety and tolerability of a first-in-kind topical formulation of a MEK kinase inhibitor, trametinib. Subjects applied daily trametinib-containing cream (0...
April 2024: Skin Health Dis
https://read.qxmd.com/read/38576937/parthenolide-induces-gallbladder-cancer-cell-apoptosis-via-mapk-signalling
#38
JOURNAL ARTICLE
Halmurat Obulkasim, Gulibositan Aji, Abudoukaher Abudoula, Yu Liu, Shaobin Duan
OBJECTIVE: Parthenolide (PTL) has a wide range of clinical applications owing to its anti-inflammatory and antitumor effects. To date, the antitumor effect of PTL on gallbladder cancer (GBC) remains largely unknown. Therefore, we aimed to investigate the biological effects of PTL on GBC. METHODS: The cellular viability and proliferation of GBC-SD and NOZ cell lines after treatment with different concentrations of PTL were analyzed using the Cell Counting Kit-8 (CCK8)assay and colony formation assay...
April 2024: Annals of Medicine and Surgery
https://read.qxmd.com/read/38576565/synergistic-effects-of-the-combination-of-trametinib-and-alpelisib-in-anaplastic-thyroid-cancer-with-braf-and-pi3kca-co-mutations
#39
JOURNAL ARTICLE
Chiao-Ping Chen, Shu-Fu Lin, Chun-Nan Yeh, Wen-Kuan Huang, Yi-Ru Pan, Yu-Tien Hsiao, Chih-Hong Lo, Chiao-En Wu
BACKGROUND: Anaplastic thyroid cancer (ATC), a rare and aggressive malignancy with a poor prognosis, has shown promise with the approved dabrafenib/trametinib combination for BRAFV600E mutation. Co-occurring PI3KCA mutations, identified as negative prognostic factors in lung cancer with BRAFV600E mutation, emphasize the need to target both pathways. Exploring trametinib and alpelisib combination becomes crucial for ATC. METHODS: A patient-derived xenograft (PDX) and primary cell line were obtained from an ATC patient with BRAF and PI3KCA co-mutation...
April 15, 2024: Heliyon
https://read.qxmd.com/read/38572608/the-treatment-of-tubal-inflammatory-infertility-using-yinjia-tablets-through-egfr-mek-erk-signaling-pathway-based-on-network-pharmacology
#40
JOURNAL ARTICLE
Yefang Huang, Zhelin He, Hang Zhou, Yi Wen, Xiaoli Ji, Weijun Ding, Boyu Zhu, Yongqing Zhang, Ying Tan, Kun Yang, Yan Wang
<p>Background: Salpingitis obstructive infertility (SOI) refers to infertility caused by abnormal conditions such as tubal adhesion and blockage caused by acute and chronic salpingitis. SOI has a serious impact on women's physical and mental health and family harmony, and it is a clinical problem that needs to be solved urgently. <p> Objective: The purpose of the present study was to explore the potential pharmacological mechanisms of the Yinjia tablets (Yin Jia Pian, YJP) on tubal inflammation...
2024: Current Pharmaceutical Biotechnology
keyword
keyword
111027
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.